ArticleScience advances2026
Aneuploidy of chromosome 8 promotes the mesenchymal lineage during cell fate transitions.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aneuploidy is present in about 90% human solid tumors. Certain tumors remain addicted to aneuploidy. Paradoxically, artificially induced aneuploidy in normal cells elicits cellular stresses and decreases cell fitness. How aneuploidy initially emerges during tumorigenesis is thus unclear. Using human embryonic stem cells (ESCs) as a model, we show that aneuploid ESCs form immature teratomas with an enrichment of mesenchymal tissues. Specifically, chromosome 8 (chr8) gain, a prevalent form of aneuploidy in human cancers, promotes the expansion of mesenchymal stem cells (MSCs) in teratomas and MSC proliferation in vitro. We further show that human embryonal rhabdomyosarcomas, tumors of mesenchymal origin, lack dominant driver mutations but frequently harbor chr8 gain. Our study suggests a plausible mechanism for aneuploidy emergence during tumorigenesis, links specific aneuploidy to the mesenchymal lineage, and paves the way for identifying vulnerabilities of aneuploid MSCs, which may have important roles in tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.